Physicians at the Mayo Clinic are highlighting how clinical trials facilitate the development of new treatments for advanced prostate cancer.
These trials are critical because they provide patients with access to emerging therapies that may be more effective than standard care. By integrating research into clinical practice, doctors can identify which treatments work best for specific patient profiles, accelerating the shift toward personalized medicine.
Jack Andrews, M.D., Mark Tyson, M.D., M.P.H., and Jacob Orme, M.D., Ph.D., of the Mayo Clinic prostate cancer team said clinical trials are the primary engine for advancing treatment options when traditional therapies fail.
Recent technological advancements are complementing these trial efforts. Automation in drug development has significantly increased efficiency, with production time for certain drug candidates reduced from six hours to 38 minutes [1]. Such speed allows researchers to test more candidates in less time.
Diagnostic precision is also improving. New blood tests can now identify if a treatment is failing within six to 12 weeks [2]. This allows physicians to pivot to alternative therapies, including those available through clinical trials, much faster than previously possible.
These developments align with broader industry discussions, such as those held during the 2026 NCCN Annual Meeting [3]. The focus remains on refining treatment selection to improve long-term patient outcomes through a combination of precise diagnostics and trial-based therapies.
“Clinical trials are the primary engine for advancing treatment options when traditional therapies fail.”
The integration of rapid drug production and early-failure detection markers reduces the 'trial and error' period for oncology patients. By shortening the time it takes to identify an ineffective treatment and accelerating the creation of new candidates, the medical community is moving toward a model where advanced prostate cancer is managed through highly iterative, data-driven interventions rather than static protocols.
